Back to discover
Drug

Peginterferon alfa-2b

Established medicine
ClassInterferon alpha/beta receptor agonistResearchOngoing clinical research
Also known as PegIntron, Peginterferon Alfa-2b (E. coli), Sylatron, Peg interferon alfa-2b+1 more

PegIntron, Peginterferon Alfa-2b (E. coli), Sylatron, Peg interferon alfa-2b, peg-interferon alfa-2b.

RxNorm253453ChEMBLCHEMBL1201561ATCL03AB10ATCL03AB60UNIIG8RGG88B68
6
Active clinical trials
2
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Clinical trial2026-06-25Results posted · ClinicalTrials.gov

A Non-randomized Controlled, Prospective, Real-world Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

Clinical trial2026-04-28Results expected Q4 2034 · ClinicalTrials.gov

A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin (RBV) in Subjects With (Genotype 1) Hepatitis C Who Did Not Respond to Previous Treatment

Clinical trial2026-01-06Results posted · ClinicalTrials.gov

A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 1 Hepatitis C Who Relapsed After Previous Treatment

Clinical trial2026-01-06Results posted · ClinicalTrials.gov

A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 2 Hepatitis C, Who Relapsed After Previous Treatment

Clinical trial2026-01-06Results posted · ClinicalTrials.gov

A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Subjects With Genotype 2 Hepatitis C, Who Did Not Respond to Previous Treatment

Clinical trial2026-01-06Results posted · ClinicalTrials.gov

A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Treatment-Naïve Subjects With Genotype 1 Hepatitis C

Clinical trial2026-01-06Results posted · ClinicalTrials.gov

Prospective Cohort Study on Pegylated Interferon Alfa-2b in Improving Clinical Cure Rate of Adolescent and Pediatric Patients With Chronic Hepatitis B Virus Infection

Clinical trial2025-11-17Results expected Q3 2028 · ClinicalTrials.gov

Real World Study of Peginterferon Alpha-2b Treatment for Inactive Chronic Hepatitis B Patients: E-Cure Study

Clinical trial2025-05-01Results expected Q4 2026 · ClinicalTrials.gov

Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for Chronic Hepatitis B in Adults

Clinical trial2025-01-15Results expected Q4 2026 · ClinicalTrials.gov

A Randomized Controlled Study Evaluating the Efficacy and Safety of Pegylated Interferon α-2b in Combination With Ruxolitinib vs. Pegylated Interferon α-2b Monotherapy for Treating Hydroxyurea-resistant/Intolerant Polycythemia Vera

Clinical trial2024-07-03Results expected Q1 2028 · ClinicalTrials.gov

A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection

Clinical trial2024-05-22Results posted · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Peginterferon alfa-2b
Aliases & brands
PegIntronPeginterferon Alfa-2b (E. coli)SylatronPeg interferon alfa-2bpeg-interferon alfa-2b
RxNorm CUI
253453
ChEMBL ID
CHEMBL1201561
ATC codes
L03AB10L03AB60
UNII
G8RGG88B68
Primary mechanism
Interferon alpha/beta receptor agonist

Pharmacology & targets

2 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Interferon alpha/beta receptor 1
IFNAR1 · P17181
AGONISTInterferon alpha/beta receptor agonist
Interferon alpha/beta receptor 2
IFNAR2 · P48551
AGONISTInterferon alpha/beta receptor agonist

Clinical trials

97 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
97
registered trials across all phases
LATEST COMPLETION 2023
6
Active studies
5
Recruiting
57
Late-stage (III+)
58
Completed
33
Discontinued
PHASE DISTRIBUTIONn = 97
Early Phase 11Phase 17Phase 1 / 24Phase 228Phase 2 / 34Phase 337Phase 410Phase N / A6

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Real World Study of Peginterferon Alpha-2b Treatment for Inactive Chronic Hepatitis B Patients: E-Cure Study

RecruitingPH IVKey trialThird Affiliated Hospital, Sun Yat-Sen Universityn=5,0002029

Prospective Cohort Study on Pegylated Interferon Alfa-2b in Improving Clinical Cure Rate of Adolescent and Pediatric Patients With Chronic Hepatitis B Virus Infection

Not yet recruitingPH IVNanfang Hospital, Southern Medical Universityn=1132028

Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor

Unknown statusPH IVThird Affiliated Hospital, Sun Yat-Sen Universityn=1002018

Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b

TerminatedPH IVUniversity of Miamin=132011

Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon

TerminatedPH IVMerck Sharp & Dohme LLCn=112008

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Multi-center, Randomized, Blinded Study to Evaluate the Efficacy and Safety of Peginterferon Alfa-2b Injection Combined With Tenofovir Disoproxil Fumarate Tablets in Patients With Chronic Hepatitis B

CompletedPH IIIXiamen Amoytop Biotech Co., Ltd.n=4752023

A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy

CompletedPH IIIKey trialChildren's Oncology Groupn=1,3342022

Induction of Graft Versus Tumor Effect of Pegylated Interferon Alpha-2b for Patients With Relapsed Hematological Malignancies After Allogeneic Stem Cell Transplantation

CompletedPH II/IIIShanghai General Hospital, Shanghai Jiao Tong University School of Medicinen=302021

Phase 1 Study of Anti-PD-1 Antibody MK-3475 and Peginterferon Alfa-2b for Advanced Melanoma

CompletedPH IHassane M. Zarour, MDn=432020

Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Philadelphia Chromosome Negative (Ph-)Chronic Myeloid Neoplasms.

CompletedPH IIIThomas Stauffer Larsenn=2022020

T Cell Therapy in Combination With Peginterferon for Patients With Metastatic Melanoma

CompletedPH I/IIInge Marie Svanen=122018
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials